查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1464773

出血性疾病诊断市场：按诊断测试、适应症和最终用途分类 - 全球预测 2024-2030

Bleeding Disorder Diagnostics Market by Diagnostic Tests (Bleeding Time, Genetic Tests, Platelet Aggregation Tests), Indication (Hemophilia A & Hemophilia B, Platelet Function Disorders, Von Willebrand Disease), End-use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

出血性疾病诊断市场规模预计2023年为6.6287亿美元，2024年达到7.1026亿美元，预计2030年将达到11.0709亿美元，复合年增长率为7.60%。

出血性疾病诊断包括用于识别和评估异常出血的根本原因的各种医学测试和程序。这些疾病，无论是先天性的还是后天性的，都会影响血液正常凝固的能力，导致轻伤导致长时间出血，严重时会导致无明显原因的自发性出血。出血性疾病的诊断方法涉及临床评估和实验室测试的组合。这些诊断的目的是准确诊断特定类型的出血性疾病，评估其严重程度，并指导适当的治疗和管理策略。准确的诊断对于实施有效的治疗和提高出血性疾病患者的生活品质至关重要。全球出血性疾病的盛行率不断增加，以及患者对这些疾病早期诊断重要性的认识不断提高，增加了对出血性疾病诊断的需求。然而，先进诊断测试的高成本可能会普及其在低收入地区的可用性，而农村和欠发达地区缺乏熟练的专业人员可能会限制其可用性。儘管存在这些挑战，旨在提高诊断准确性和降低成本的持续研究和开发工作为提高全球出血性疾病诊断的可近性和普及提供了新的成长途径。

主要市场统计
基准年[2023] 66287万美元
预测年份 [2024] 71026万美元
预测年份 [2030] 1,107.09百万美元
复合年增长率（%） 7.60%

诊断测试：识别与凝血因子相关的特定基因的突变和异常的基因测试将变得越来越重要。

出血时间是一种传统的诊断测试，旨在评估初步止血情况，通常评估在前臂下侧切开小切口后血管止血所需的时间。此测试反映了血小板与血管壁的相互作用，但不直接测量凝血因子活性。出血性疾病基因检测分析人类的 DNA，以识别导致出血性疾病的基因异常或突变。这些检查对于诊断遗传性出血性疾病特别有用，例如A型血友病和乙型血友病、冯·维勒布兰德病和其他罕见的凝血因子缺乏症。基因检测提供明确的诊断，支持基因带原检测，深入了解疾病的严重程度，并指南治疗决策。血小板凝集测试是一系列测试，用于评估血小板（一种对血液凝固很重要的血球）聚集形成血块的程度。这些检验评估血小板针对各种凝聚剂（例如 ADP、胶原蛋白、瑞斯托菌素和肾上腺素）的功能。

适应症：出血性疾病诊断对诊断不同类型VWD的重要应用

A型血友病，也称为经典血友病，是一种由凝血因子VIII缺乏引起的遗传性疾病。这种疾病会导致受伤或手术后过度或自发性出血，尤其是肌肉和关节。它发生在男性中，并以 X 连锁隐性方式遗传。 B型血友病，也称为圣诞节病，是由凝血因子 IX 缺乏引起的。其临床症状与A型血友病相似，但较少见。血小板功能障碍是一组以血小板无法有效促进血液凝固，导致异常出血为特征的疾病。这些疾病可能是先天性的，例如格兰兹曼血栓无力或伯纳德-苏利埃综合征，也可能是由于其他医疗状况或药物引起的。症状包括伤口流血过多、容易瘀青和长时间流血。血小板计数测试、血小板功能检查和出血时间测试通常用于诊断这些疾病。冯·维勒布兰氏症(VWD) 是一种常见的遗传性出血性疾病，由冯·维勒布兰德因子(VWF) 功能障碍或缺乏引起，冯·维勒布兰德因子是血栓形成的关键蛋白。根据 VWF 的数量或品质缺陷，VWD 可分为三种主要类型。患者可能会出现自发性出血、外伤或外科手术期间出血过多或月经期间大量出血。 VVD 的诊断很复杂，包括评估患者的出血史、VWF 抗原检测以及评估 VWF 和因子 VIII 活性的功能测试。

区域洞察

在美洲，尤其是北美，出血性疾病诊断市场正在经历强劲成长。美国因其高度发展的医疗基础设施、大量的研发投资以及主要市场参与企业的强大影响力而成为这一增长的主要贡献者。大量的A型血友病和B型血友病血友病患者以及支持性报销政策进一步增强了该地区出血性疾病诊断的需求。欧洲、中东和非洲地区由于不同的经济、医疗和监管情况，呈现不同的市场表现。由于高意识、强大的医疗保健系统以及对出血性疾病诊断的大量投资，欧洲保持了强劲的市场成长。然而，儘管中东和非洲的成长率有所放缓，但在发展医疗基础设施和改善诊断机会的支持下，成长率正在逐渐上升。由于医疗保健支出的增加和提高医疗保健标准的努力，中东地区的前景尤其乐观。由于人口众多、医疗成本不断上升以及对出血性疾病的认识不断提高，亚太地区已成为出血性疾病诊断快速增长的市场。由于医疗基础设施的扩大、出血性疾病数量的增加以及政府为改善医疗服务所做的努力，该地区的新兴国家正在迅速采用出血性疾病诊断解决方案。

FPNV定位矩阵

FPNV 定位矩阵对于评估出血性疾病诊断市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限。最前线 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市场占有率分析

市场占有率分析是一种综合工具，可以对出血性疾病诊断市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该细分市场竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：包括新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：包括对未来技术、研发活动以及突破性产品开发的见解。

本报告解决了以下关键问题：

1.出血性疾病诊断市场的市场规模与预测为何？

2.在出血性疾病诊断市场的预测期间内，有哪些产品、细分市场、应用和细分市场需要考虑投资？

3.出血性疾病诊断市场的技术趋势和法规结构是什么？

4.出血性疾病诊断市场主要供应商的市场占有率为何？

5. 进入出血性疾病诊断市场的适当型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 出血性疾病盛行率增加
      • 公众和医疗保健专业人员对出血性疾病的认识和承诺正在不断增强
    • 抑制因素
      • 与先进的出血性疾病诊断方法相关的高成本
    • 机会
      • 尖端技术诊断出血性疾病的新可能性
      • 更多采用照护现场出血性疾病检测设备
    • 任务
      • 不同地区医疗保健监管的复杂性与动态性
  • 市场区隔分析
    • 诊断测试：用于识别与凝血因子相关的特定基因的突变和异常的基因测试变得越来越重要。
    • 适应症：出血性疾病诊断对于诊断各类VWD的重要应用
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章出血性疾病诊断市场：透过诊断测试

  • 介绍
  • 出血时间
  • 基因检测
  • 血小板凝集试验

第七章出血性疾病诊断市场：依适应症分类

  • 介绍
  • A型血友病 A和B型血友病
  • 血小板功能障碍
  • 血管性血友病

第八章出血性疾病诊断市场：依最终用途分类

  • 介绍
  • 诊断实验室
  • 医院
  • 专科诊所

第九章美洲出血性疾病诊断市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太出血性疾病诊断市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章：欧洲、中东和非洲出血性疾病诊断市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-8E373E9E2067

[198 Pages Report] The Bleeding Disorder Diagnostics Market size was estimated at USD 662.87 million in 2023 and expected to reach USD 710.26 million in 2024, at a CAGR 7.60% to reach USD 1,107.09 million by 2030.

Bleeding disorder diagnostics encompass a range of medical tests and procedures used to identify and evaluate the underlying causes of abnormal bleeding. These disorders, which can be either congenital or acquired, affect the blood's ability to coagulate properly, leading to prolonged bleeding even from minor injuries or, in severe cases, spontaneous bleeding without any apparent cause. Diagnostic approaches for bleeding disorders include a combination of clinical assessments and laboratory testing. The goal of these diagnostics is to accurately diagnose the specific type of bleeding disorder, assess its severity, and guide appropriate treatment and management strategies. Accurate diagnosis is crucial for implementing effective treatments and improving the quality of life for individuals with bleeding disorders. The rising prevalence of bleeding disorders worldwide, coupled with a growing awareness among patients about the importance of early diagnosis of these conditions, is bolstering the need for bleeding disorder diagnostics. However, the high cost of advanced diagnostic tests, which may limit their accessibility in low-income regions, and the shortage of skilled professionals in rural and underdeveloped areas pose significant challenges to the widespread adoption of these diagnostic solutions. Despite these challenges, ongoing research and development activities aimed at enhancing diagnostic accuracy and reducing costs offer new growth avenues for improved accessibility and adoption of bleeding disorder diagnostics worldwide.

KEY MARKET STATISTICS
Base Year [2023] USD 662.87 million
Estimated Year [2024] USD 710.26 million
Forecast Year [2030] USD 1,107.09 million
CAGR (%) 7.60%

Diagnostic Tests: Growing importance of genetic testing to identify mutations or abnormalities in specific genes associated with clotting factors

Bleeding time is a traditional diagnostic test designed to evaluate primary hemostasis and assess the duration it takes for blood vessels to cease bleeding after a small incision, typically on the underside of the forearm. It reflects the interaction between platelets and the vascular wall but does not measure clotting factor activity directly. Genetic testing in the context of bleeding disorders involves analyzing an individual's DNA to identify genetic abnormalities or mutations that may lead to a bleeding disorder. These tests are particularly valuable for diagnosing inherited bleeding disorders, including hemophilia A and B, Von Willebrand disease, and other rare clotting factor deficiencies. Genetic tests provide definitive diagnoses, enable carrier testing, offer insights into disease severity, and guide treatment decisions. Platelet aggregation tests are a suite of assays used to evaluate how well platelets, a type of blood cell crucial for clotting, clump together to form a blood clot. These tests assess the function of platelets in response to various aggregating agents such as ADP, collagen, ristocetin, and epinephrine.

Indication: Significant applications of bleeding disorder diagnostics to diagnose different types of VWD

Hemophilia A, also referred to as classical hemophilia, is a genetic disease caused by a deficiency of clotting factor VIII. This condition leads to excessive bleeding following injury or surgery and spontaneous bleeding episodes, notably in muscles and joints. It affects males, being passed on through an X-linked recessive pattern. Hemophilia B, also called Christmas disease, is caused by a deficiency of clotting factor IX. Its clinical manifestations are similar to Hemophilia A, though it is less common. Platelet function disorders are a group of conditions characterized by the inability of platelets to effectively contribute to blood clotting, leading to abnormal bleeding. These disorders can be congenital, such as Glanzmann thrombasthenia or Bernard-Soulier syndrome, or acquired due to other medical conditions or medications. Symptoms include excessive bleeding from wounds, easy bruising, and prolonged bleeding times. Diagnosis of these disorders typically involves platelet count tests, platelet function assays, and bleeding time tests. Von Willebrand Disease (VWD) is one of the common inherited bleeding disorders caused by a dysfunction or deficiency of the von Willebrand factor (VWF), a major protein in blood clot formation. VWD is categorized into three main types based on the quantitative or qualitative defect of VWF. Patients may experience spontaneous bleeding, excessive bleeding during injury or surgical procedures, and heavy menstrual bleeding. Diagnosis of VVD is complex and includes evaluating the patient's bleeding history, VWF antigen tests, and functional assays to assess the activity of VWF and factor VIII.

Regional Insights

In the Americas, particularly in North America, the market for bleeding disorder diagnostics is experiencing robust growth. The United States contributes majorly to this growth with a highly advanced healthcare infrastructure, significant investments in R&D, and a strong presence of major market players. A significant number of hemophilia A & hemophilia B patients and supportive reimbursement policies further fuel the need for bleeding disorder diagnostics in the region. The EMEA region shows a diverse market performance owing to varying economic, healthcare, and regulatory landscapes. Europe maintains a strong market growth with high awareness levels, strong healthcare systems, and significant investments in bleeding disorders diagnostics. However, growth rates in the Middle East and Africa are slower but gradually increasing, driven by efforts to improve healthcare infrastructure and access to diagnostics. The Middle East, in particular, shows promise with rising healthcare expenditure and initiatives to enhance healthcare standards. The APAC region is emerging as a rapidly growing market for bleeding disorder diagnostics, attributed to its large population base, increasing healthcare expenditure, and growing awareness of bleeding disorders. Emerging economies in the region are rapidly adopting bleeding disorder diagnostics solutions owing to their expanding healthcare infrastructure, rise in bleeding disorders, and initiatives by governments to improve healthcare access.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Bleeding Disorder Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Bleeding Disorder Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Bleeding Disorder Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ARUP Laboratories, Baxter International Inc., Bayer AG, Bio-Rad Laboratories, Inc., Cepheid by Danaher Corporation, CSL Limited, F. Hoffmann-La Roche Ltd., HORIBA, Ltd., Hyphen BioMed by Sysmex Corporation, Laboratory Corporation of America Holdings, Novo Nordisk A/S, Precision BioLogic, rHEALTH, Siemens AG, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Bleeding Disorder Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Diagnostic Tests
    • Bleeding Time
    • Genetic Tests
    • Platelet Aggregation Tests
  • Indication
    • Hemophilia A & Hemophilia B
    • Platelet Function Disorders
    • Von Willebrand Disease
  • End-use
    • Diagnostic Laboratories
    • Hospitals
    • Specialized Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Bleeding Disorder Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Bleeding Disorder Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Bleeding Disorder Diagnostics Market?

4. What is the market share of the leading vendors in the Bleeding Disorder Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Bleeding Disorder Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of bleeding disorders
      • 5.1.1.2. Growing awareness and initiatives about bleeding disorders among the general population and healthcare professionals
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with advanced bleeding disorder diagnostics methods
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging potential of advanced technologies in bleeding disorder diagnostics
      • 5.1.3.2. Growing adoption of point-of-care bleeding disorder testing devices
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory complexities and the dynamic nature of healthcare regulations across different regions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Diagnostic Tests: Growing importance of genetic testing to identify mutations or abnormalities in specific genes associated with clotting factors
    • 5.2.2. Indication: Significant applications of bleeding disorder diagnostics to diagnose different types of VWD
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Bleeding Disorder Diagnostics Market, by Diagnostic Tests

  • 6.1. Introduction
  • 6.2. Bleeding Time
  • 6.3. Genetic Tests
  • 6.4. Platelet Aggregation Tests

7. Bleeding Disorder Diagnostics Market, by Indication

  • 7.1. Introduction
  • 7.2. Hemophilia A & Hemophilia B
  • 7.3. Platelet Function Disorders
  • 7.4. Von Willebrand Disease

8. Bleeding Disorder Diagnostics Market, by End-use

  • 8.1. Introduction
  • 8.2. Diagnostic Laboratories
  • 8.3. Hospitals
  • 8.4. Specialized Clinics

9. Americas Bleeding Disorder Diagnostics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Bleeding Disorder Diagnostics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Bleeding Disorder Diagnostics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. ARUP Laboratories Makes History with Diagnostic Test for Hemophilia A
    • 12.3.2. FDA Approves First Gene Therapy for Adults with Severe Hemophilia A
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BLEEDING DISORDER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BLEEDING DISORDER DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLEEDING DISORDER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLEEDING TIME, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY BLEEDING TIME, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET AGGREGATION TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA A & HEMOPHILIA B, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HEMOPHILIA A & HEMOPHILIA B, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET FUNCTION DISORDERS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY PLATELET FUNCTION DISORDERS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 33. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 34. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 39. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 40. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 41. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 42. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 45. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 46. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 47. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 48. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 51. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 52. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 53. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 54. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 57. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 58. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 59. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 60. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 63. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 64. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 65. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 80. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 82. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 85. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 86. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 87. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 91. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 92. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 93. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 94. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 97. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 98. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 99. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 100. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 103. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 104. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 105. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 109. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 110. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 111. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 116. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 121. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 122. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 123. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 128. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 133. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 134. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 135. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 139. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 140. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 141. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 142. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 145. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 146. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 147. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 159. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 160. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 161. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 165. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 166. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 167. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 168. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 171. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 172. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 173. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 174. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 177. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 178. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 179. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 183. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 184. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 185. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 186. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 189. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 190. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 191. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 195. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 196. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 197. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 198. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 202. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 204. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 207. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 208. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 209. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 210. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 213. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 214. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 215. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 216. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 219. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 220. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 221. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 225. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 226. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 227. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 228. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 231. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 232. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 233. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 234. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 238. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 240. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 244. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 249. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 250. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 251. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 252. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 255. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 256. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 257. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 262. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 264. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 267. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 268. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 269. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 270. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TESTS, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM BLEEDING DISORDER DIAGNOSTICS MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 285. BLEEDING DISORDER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. BLEEDING DISORDER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023